- Registration Date 2016-03-24
- Hit 3687
Company Information |
|
1. Name |
Celltrion, Inc. |
2. Website Address |
http://www.celltrion.com/en/main.do |
3. Location |
Plant 1: 23, Academy ro, Yeonsu-gu, Incheon, Republic of Korea Plant 2: 19, Academy ro 51beon-gil, Yeonsu-gu, Incheon, Republic of Korea |
4. Contacts |
Business : contact@celltrion.com Investment Relations : investor@celltrion.com |
Pharmaceutical Product Information |
|
1. Brand Name |
RemsimaⓇ |
2. Active Ingredient |
Infliximab |
3. Indication |
Rheumatoid Arthritis, Ankylosing Spondylitis, Adult Crohn’s Disease, Pediatric Crohn’s Disease, Ulcerative Colitis, Pediatric Ulcerative Colitis, Psoriatic Arthritis, Plaque Psoriasis |
4. Information |
The world first biosimilar monoclonal antibody(mAb), approved in 79 countries including MFDS(2012), EMA(2013) and FDA(2016). Remsima is a tumor necrosis factor α (TNF-α) antagonist used to treat rheumatoid arthritis, ankylosing spondylitis, ulcerative colitis, pediatric ulcerative colitis, adult Crohn's disease, pediatric Crohn’s disease, plaque psoriasis, and psoriatic arthritis. |
5. Images |
|
Pharmaceutical Product Information |
|
1. Brand Name |
TruximaⓇ |
2. Active Ingredient |
Rituximab |
3. Indication |
Non-Hodgkin’s lymphoma (NHL), Chronic lymphocytic leukaemia (CLL), Rheumatoid arthritis, Granulomatosis with polyangiitis and microscopic polyangiitis |
4. Information |
A monoclonal antibody biosimilar approved by MFDS in 2016. Truxima is an antibody against CD20 intended for the treatment of non-Hodgkin’s lymphoma, chronic lymphocytic leukaemia, rheumatoid arthritis, granulomatosis with polyangiitis and microscopic polyangiitis. |
5. Images |
|
Pharmaceutical Product Information |
|
1. Brand Name |
HerzumaⓇ (150mg / 440mg) |
2. Active Ingredient |
Trastuzumab |
3. Indication |
early breast cancer, metastatic breast cancer, metastatic gastric cancer |
4. Information |
A humanized monoclonal antibody(mAb) biosimilar approved by MFDS in 2014. Herzuma is an antibody against epidermal growth factor (EGF) receptor 2 (HER2; ErbB2; neu) to treat early breast cancer, metastatic breast cancer, metastatic gastric cancer. |
5. Images |
|
Division
Written by 한지혜